Anticoagulation in COVID pneumonia (ATTACC)
Principal Investigator(s):
Ryan Zarychanski, Alexis Turgeon, Patrick Lawler, Ewan Goligher
Status:
Enrolment Complete
See publication: Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 (2021)
In noncritically ill patients with Covid-19, an initial strategy of therapeutic-dose anticoagulation with heparin increased the probability of survival to hospital discharge with reduced use of cardiovascular or respiratory organ support as compared with usual-care thromboprophylaxis.